Low-level laser therapy (LLLT) for hair loss — delivered through devices such as laser caps, combs, and helmets — has grown into a significant market, with devices available direct to consumers at prices ranging from £200 to over £2,000. The question patients ask is whether the evidence supports the investment.
LLLT works by delivering photons of specific wavelengths (typically 630 to 670nm, red light) to the scalp tissue. The proposed mechanism is photo-biomodulation — the stimulation of mitochondrial activity in hair follicle cells, which is thought to increase cellular energy production and prolong the anagen (growth) phase.
The evidence base is modest but more substantive than for many cosmetic treatments. Several randomised controlled trials have shown increases in hair count and density with LLLT versus sham devices, particularly in patients with androgenetic alopecia at early to moderate stages. The effect size is generally smaller than that seen with finasteride or minoxidil.
LLLT appears most useful as a complementary therapy — used alongside finasteride or minoxidil to add an incremental benefit, rather than as a standalone treatment expected to produce significant results independently. Patients who use multiple evidence-based approaches tend to do better than those relying on any single treatment.
The devices must be used consistently — typically three times per week for at least six months before any benefit is visible. Stopping treatment causes the benefit to regress, as with all hair loss treatments.
Related reading
